Cover Image

Editorial: NAFLD, NAFLD, or MASLD: what's in a name?

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Maryam Zafer, Shravan Dave
Format:	Artículo Open Access
Published:	Wiley 2024
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Letter: Enhancing cirrhosis management—The critical role of social workers in supporting NAFLD surveillance
by: Senlin Ye, et al.
Published: (2024)

Editorial: Checkpoint Inhibitor‐Induced Liver Injury—Time to Abandon CTCAE?
by: Kelly Torosian, et al.
Published: (2024)

Review Article: GLP‐1 Receptor Agonists and Glucagon/GIP/GLP‐1 Receptor Dual or Triple Agonists—Mechanism of Action and Emerging Therapeutic Landscape in MASLD
by: Maryam Zafer, et al.
Published: (2025)

Editorial: Cardiometabolic criteria matters inMASLD
by: Margaret L. P. Teng, et al.
Published: (2024)

Editorial: Hyperferritinaemia—An Ironclad Biomarker for the Prognostication of MASLD?
by: Mark C. C. Cheah, et al.
Published: (2025)

Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)!
by: Hannah Mohr, et al.
Published: (2025)

Editorial: Accelerometers to Quantify Physical Activity in MASLD—Impact on Clinical Outcomes
by: Vincent L. Chen
Published: (2025)

Editorial: Enriching our understanding of MASLD through representation of under‐reported populations
by: Niharika Samala, et al.
Published: (2024)

Editorial: Refining the Natural History of MASLD by Imaging‐Based Markers: The GOLDMINE Study
by: Federico Perna, et al.
Published: (2026)

Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification
by: Takefumi Kimura
Published: (2025)

Editorial: Polypharmacy in MASLD—An Overlooked Epidemic Disproportionately Affecting Women and Patients With Cirrhosis
by: Mary Yue Wang, et al.
Published: (2025)

Editorial: ABID‐LSM–A Promising Model for Predicting Decompensation Risk in MASLD Cirrhosis
by: Eduardo Vilar‐Gomez, et al.
Published: (2025)

Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD —Insights From a National Analysis. Authors' Reply
by: Donghee Kim, et al.
Published: (2025)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations
by: Jiru Li, et al.
Published: (2025)

Editorial: Beyond Clinical Trials—Real‐World Data Suggest Usefulness of GLP‐1 RAs in MASLD Treatment. Authors' Reply
by: Chia‐Chih Kuo, et al.
Published: (2025)

Global Longitudinal Assessment of MASLD Using Magnetic Resonance Elastography ( GOLDMINE ): A Multi‐Center, International Prospective Cohort Study of Imaging Biomarkers in MASLD Clinical Outcomes
by: Suzanne Sharpton, et al.
Published: (2026)

Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
by: Wah‐Kheong Chan, et al.
Published: (2024)

Volatomics for Diagnosis and Risk Stratification of MASLD: A Proof‐Of‐Concept Study
by: R. Sinha, et al.
Published: (2025)

Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD
by: Hassan Javed, et al.
Published: (2025)

A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
by: Maral Amangurbanova, et al.
Published: (2024)

Gastrointestinal Cancer Risk in Steatotic Liver Diseases: MASLD , MetALD and ALD
by: Nobuharu Tamaki, et al.
Published: (2025)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
by: Mohamed El‐Kassas, et al.
Published: (2025)

Editorial: Does Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD ) With Advanced Fibrosis Also Equate to Risk of Advanced Coronary Artery Disease?
by: C. C. Mark Cheah, et al.
Published: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing?
by: Qiang Hu, et al.
Published: (2024)

Prevalence of Low FIB‐4 in MASLD‐Related Hepatocellular Carcinoma: A Multicentre Study
by: Darren Jun Hao Tan, et al.
Published: (2024)

Letter: A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
by: Xiaojuan Liu, et al.
Published: (2025)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
by: Stuart McPherson, et al.
Published: (2024)

The Proteomics of MASLD Progression: Insights From Functional Analysis to Drive the Development of New Therapeutic Solutions
by: Carlos José Pirola, et al.
Published: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
by: Yewan Park, et al.
Published: (2024)

Letter: Clarifying the Synergistic Mechanisms of Mediterranean Diet and Time‐Restricted Feeding in MASLD Management—Authors' Reply
by: Sofia Tsitsou, et al.
Published: (2025)

MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls
by: Daniela S. Allende, et al.
Published: (2024)

Lubiprostone Reduces Fat Content on MRI‐PDFF in Patients With MASLD: A 48‐Week Randomised Controlled Trial
by: Mohamed El‐Kassas, et al.
Published: (2025)

Prevalence and prognosis of patients with MASLD ‐related cirrhosis after an ICU hospitalization in France: A single‐centre prospective study
by: Philippe Sultanik, et al.
Published: (2024)

Letter: Using non‐invasive fibrosis tests and emerging diagnostics to enhance the accuracy of liver fibrosis staging in MASLD patients
by: Wenjun Meng, et al.
Published: (2024)

Letter: MASLD in people with HIV exhibits higher fibrosis stage despite lower disease activity than in matched controls
by: Junbin Yan, et al.
Published: (2024)

The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET‐NASH
by: Brent A. Neuschwander‐Tetri, et al.
Published: (2025)

Testing in functional constipation—What's new and what works
by: Leonel Rodriguez
Published: (2024)

Serum growth differentiation factor 15 is a novel biomarker with high predictive capability for liver cancer occurrence in patients with MASLD regardless of liver fibrosis
by: Shusuke Kumazaki, et al.
Published: (2024)

Head‐to‐Head Comparison Between Phosphatidylethanol Versus Indirect Alcohol Biomarkers for Diagnosis of MetALD Versus MASLD: A Prospective Study
by: Federica Tavaglione, et al.
Published: (2025)

Anthropometric Measures and Mortality Risk in Individuals With Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD): A Population‐Based Cohort Study
by: Yee Hui Yeo, et al.
Published: (2025)